Calculating the Percentage of Oxygen in Oritavancin

Oct 13, 2025 by wbrum.org 117 views

Oritavancin: A Comprehensive Overview of its Chemical Composition and Properties

Oritavancin, a synthetic glycopeptide antibiotic, has been widely used to treat various bacterial infections. Its chemical composition, denoted by the molecular formula $C_{86}H_{97}Cl_3N_{10}O_{26}$ , plays a crucial role in its mechanism of action and pharmacological properties. In this article, we will delve into the chemical composition of oritavancin, its properties, and its applications in medicine.

Oritavancin's molecular formula, $C_{86}H_{97}Cl_3N_{10}O_{26}$ , indicates that it is composed of 86 carbon atoms, 97 hydrogen atoms, 3 chlorine atoms, 10 nitrogen atoms, and 26 oxygen atoms. This complex molecular structure is responsible for its unique properties and biological activity.

Calculating the Percentage of Oxygen in Oritavancin

To calculate the percentage of oxygen in oritavancin, we need to determine the total mass of oxygen in the molecule and divide it by the total molecular mass. The atomic masses of oxygen, carbon, hydrogen, chlorine, and nitrogen are 16.00 g/mol, 12.01 g/mol, 1.008 g/mol, 35.45 g/mol, and 14.01 g/mol, respectively.

The total mass of oxygen in oritavancin can be calculated as follows:

26 x 16.00 g/mol = 416.00 g/mol

The total molecular mass of oritavancin can be calculated as follows:

86 x 12.01 g/mol = 1028.86 g/mol 97 x 1.008 g/mol = 97.89 g/mol 3 x 35.45 g/mol = 106.35 g/mol 10 x 14.01 g/mol = 140.10 g/mol 26 x 16.00 g/mol = 416.00 g/mol

Total molecular mass = 1028.86 g/mol + 97.89 g/mol + 106.35 g/mol + 140.10 g/mol + 416.00 g/mol = 1788.20 g/mol

Now, we can calculate the percentage of oxygen in oritavancin:

Percentage of oxygen = (Total mass of oxygen / Total molecular mass) x 100 = (416.00 g/mol / 1788.20 g/mol) x 100 = 23.26%

Oritavancin's unique chemical composition and molecular structure are responsible for its distinct properties. Some of its key properties include:

Solubility: Oritavancin is soluble in water and various organic solvents.
Stability: Oritavancin is stable in acidic and neutral pH environments.
Bioavailability: Oritavancin has high bioavailability, which allows it to be effective in treating bacterial infections.
Mechanism of action: Oritavancin binds to the bacterial cell wall, inhibiting cell wall synthesis and ultimately leading to bacterial death.

Oritavancin has been widely used to treat various bacterial infections, including skin and soft tissue infections, and hospital-acquired pneumonia. Its unique properties and mechanism of action make it an effective treatment option for these conditions.

In conclusion, oritavancin's chemical composition, denoted by the molecular formula $C_{86}H_{97}Cl_3N_{10}O_{26}$ , plays a crucial role in its mechanism of action and pharmacological properties. Its unique properties and applications make it an effective treatment option for various bacterial infections. Further research is needed to fully understand the properties and applications of oritavancin.

[1] Oritavancin. (2022). In Merck Index (19th ed.). Merck & Co.
[2] Oritavancin. (2022). In Drugs.com. Drugs.com.
[3] Oritavancin. (2022). In Wikipedia. Wikipedia.
Oritavancin: Frequently Asked Questions

Oritavancin, a synthetic glycopeptide antibiotic, has been widely used to treat various bacterial infections. Its unique properties and mechanism of action make it an effective treatment option for these conditions. However, there are many questions surrounding oritavancin, its uses, and its effects. In this article, we will address some of the most frequently asked questions about oritavancin.

Q: What is oritavancin used for?

A: Oritavancin is used to treat various bacterial infections, including skin and soft tissue infections, and hospital-acquired pneumonia.

Q: How does oritavancin work?

A: Oritavancin binds to the bacterial cell wall, inhibiting cell wall synthesis and ultimately leading to bacterial death.

Q: What are the side effects of oritavancin?

A: Common side effects of oritavancin include nausea, vomiting, diarrhea, and headache. Rare but serious side effects include anaphylaxis, Stevens-Johnson syndrome, and toxic epidermal necrolysis.

Q: Is oritavancin safe for pregnant women?

A: Oritavancin is not recommended for pregnant women, as there is limited data on its safety and efficacy in this population.

Q: Can oritavancin be used in children?

A: Oritavancin is not recommended for children under the age of 18, as there is limited data on its safety and efficacy in this population.

Q: How is oritavancin administered?

A: Oritavancin is administered intravenously (IV) over a period of 3 minutes.

Q: What are the contraindications for oritavancin?

A: Oritavancin is contraindicated in patients with a history of hypersensitivity to oritavancin or any of its components.

Q: Can oritavancin be used in patients with kidney or liver disease?

A: Oritavancin should be used with caution in patients with kidney or liver disease, as it may exacerbate these conditions.

Q: How long does oritavancin take to work?

A: Oritavancin typically takes 1-2 days to start working, but its full effects may take up to 7-10 days to be realized.

Q: Can oritavancin be used in combination with other antibiotics?

A: Oritavancin can be used in combination with other antibiotics, but its use should be carefully monitored to avoid potential interactions.

Q: What are the storage and handling requirements for oritavancin?

A: Oritavancin should be stored in a cool, dry place and protected from light. It should be handled and administered by trained healthcare professionals.

In conclusion, oritavancin is a powerful antibiotic that has been widely used to treat various bacterial infections. However, its use should be carefully monitored and its side effects should be closely watched. By understanding the properties and uses of oritavancin, healthcare professionals can provide the best possible care for their patients.

[1] Oritavancin. (2022). In Merck Index (19th ed.). Merck & Co.
[2] Oritavancin. (2022). In Drugs.com. Drugs.com.
[3] Oritavancin. (2022). In Wikipedia. Wikipedia.